Patents by Inventor Gary A. Shangold
Gary A. Shangold has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100063019Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Applicants: Duramed Pharmaceuticals, Inc., Jencap Research Ltd.Inventors: Robert F. CASPER, Gary A. SHANGOLD, Militza K. AUSMANAS
-
Publication number: 20080182828Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: ApplicationFiled: November 27, 2007Publication date: July 31, 2008Applicants: Duramed Pharmaceuticals, Inc., Jencap Research Ltd.Inventors: Robert F. CASPER, Gary A. SHANGOLD, Militza K. AUSMANAS
-
Patent number: 7320970Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: GrantFiled: May 24, 2006Date of Patent: January 22, 2008Assignees: Duramed Pharmaceutials, Inc., Jencap Research Ltd.Inventors: Robert F. Casper, Gary A. Shangold, Militza K. Ausmanas
-
Publication number: 20060211663Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: ApplicationFiled: May 24, 2006Publication date: September 21, 2006Applicant: Duramed Pharmaceuticals, Inc.Inventors: Robert Casper, Gary Shangold, Militza Ausmanas
-
Patent number: 7078394Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17?-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 ?g per day of norgestimate.Type: GrantFiled: March 22, 2004Date of Patent: July 18, 2006Assignee: Duramed Pharmaceuticals, Inc.Inventors: Robert F. Casper, Gary A. Shangold, Militza K. Ausmanas
-
Publication number: 20050038006Abstract: A method of contraception in which an estrogen and desogestrel are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 ?g of 17?-ethinylestradiol and in progestogenic activity to 0.065-0.75 of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen, provided that the progestin dose should increase from the first phase to the second phase to the third phase, that the progestin is desogestrel at a dose in each phase of between of from 0.Type: ApplicationFiled: September 21, 2004Publication date: February 17, 2005Inventors: Gary Shangold, Arkady Rubin, David Upmalis
-
Publication number: 20040180867Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &mgr;g per day of norgestimate.Type: ApplicationFiled: March 22, 2004Publication date: September 16, 2004Inventors: Robert F. Casper, Gary A. Shangold, Militza K. Ausmanas
-
Patent number: 6747019Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &mgr;g per day of norgestimate.Type: GrantFiled: April 30, 2002Date of Patent: June 8, 2004Assignees: Jencap Research, Ltd., Ortho-McNeil Pharmaceutical, Inc.Inventors: Robert F. Casper, Gary A. Shangold, Militza K. Ausmanas
-
Publication number: 20020165209Abstract: A hormone replacement therapy, comprising a plurality of daily doses of a pharmaceutical preparation, the doses being administered continuously and consecutively in alternating phases of three daily doses, a relatively dominant estrogenic activity phase comprising three daily doses of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol per day, and a relatively dominant progestagenic activity phase of a combination of a substance exhibiting estrogenic activity equivalent to about 1 mg per day of 17&bgr;-estradiol and a substance exhibiting progestogenic activity equivalent to about 90 &mgr;g per day of norgestimate.Type: ApplicationFiled: April 30, 2002Publication date: November 7, 2002Applicant: Jencap Research Ltd.Inventors: Robert F. Casper, Gary A. Shangold, Militza K. Ausmanas
-
Publication number: 20010044429Abstract: A method of contraception in which an estrogen and desogestrel are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 &mgr;g of 17&agr;-ethinylestradiol and in progestogenic activity to 0.065-0.75 of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.Type: ApplicationFiled: February 13, 2001Publication date: November 22, 2001Inventors: Gary A. Shangold, Arkady Rubin, David Upmalis
-
Patent number: 6214815Abstract: A method of contraception in which an estrogen and a progestogen are administered daily in a three phase sequence for 21 days is disclosed. In the first phase a combination of an estrogen and a progestogen in a low but contraceptively effective daily dosage corresponding in estrogenic activity to 23-28 &mgr;g of 17&agr;-ethinylestradiol and in progestogenic activity to 0.065-0.75 mg of norethindrone is administered for 5-8 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.25-1.0 mg of norethindrone for 7-11 days; followed by the administering of the same dosage of estrogen and a progestogen corresponding in progestogenic activity to 0.35-2.0 mg of norethindrone for 3-7 days; followed by 4-8 days without administering either an estrogen or a progestogen.Type: GrantFiled: June 9, 1999Date of Patent: April 10, 2001Assignee: Ortho-McNeil Pharmaceuticals, Inc.Inventors: Gary Shangold, Arkady Rubin, David Upmalis
-
Patent number: 5951762Abstract: An apparatus for housing a plurality of applicators in a hygienic cavity and dispensing said plurality of applicators from said cavity. The apparatus includes a container for holding said plurality of applicators, a support structure for the plurality of applicators, a reservoir in fluid communication with the hygienic cavity, said reservoir being situated to facilitate wetting said plurality of applicators with said fluid during said dispensing; an aperture generally adjacent to said reservoir; said plurality of applicators traversing said aperture during said dispensing; and a dispenser structure actuable by a user from outside said container to engage at least one applicator of said plurality of applicators for causing advancement of said at least one applicator through said aperture to effect said dispensing.Type: GrantFiled: June 27, 1997Date of Patent: September 14, 1999Inventors: Gary A. Shangold, Joel Lippman
-
Patent number: 5660636Abstract: An apparatus for housing a plurality of applicators in a hygienic cavity and dispensing said plurality of applicators from said cavity. The apparatus includes a container for holding said plurality of applicators, a support structure for the plurality of applicators, a reservoir in fluid communication with the hygienic cavity, said reservoir being situated to facilitate wetting said plurality of applicators with said fluid during said dispensing; an aperture generally adjacent to said reservoir; said plurality of applicators traversing said aperture during said dispensing; and a dispenser structure actuable by a user from outside said container to engage at least one applicator of said plurality of applicators for causing advancement of said at least one applicator through said aperture to effect said dispensing.Type: GrantFiled: March 21, 1995Date of Patent: August 26, 1997Inventors: Gary A. Shangold, Joel Lippman